Sector News

Deal-weighing Pharmacyclics could draw $18B from J&J, Novartis: Bloomberg

February 26, 2015
Life sciences
So far, the 2014 pharma deal blitz has continued right on into 2015. And cancer drugmaker Pharmacyclics could be the next company to keep it going.
 
The California company, which boasts a market value of almost $15 billion, is exploring its options–and those include a sale, Bloomberg’s sources say. While deliberations are still in the early stages, Pharmacyclics already reportedly has some big-name suitors circling, including Johnson & Johnson and Novartis.
 
While a potential deal for the Sunnyvale-based company–which could draw bids as high as $17 billion or $18 billion, Bloomberg notes–would be the biggest in the industry so far this year, it’s nothing the pharma giants couldn’t swallow. And drugmakers may be eager to get their hands on Imbruvica, the blood cancer drug that last month scored its fourth FDA approval.
 
For J&J, the fit would be natural. Its Janssen subsidiary already markets the med outside the U.S. and shares marketing duties with Pharmacyclics at home, and the pair is working together to try to expand Imbruvica’s patient pool. But J&J isn’t the company’s only partner; it’s also teamed up with drugmakers the likes of Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene and Roche  to study Imbruvica as part of cancer-fighting combos.
 
And for Novartis, which already boasts a pair of blood-cancer powerhouse treatments in Gleevec and Tasigna, the pickup makes sense, too. The Basel-based pharma giant has been active in the M&A arena as it rides pharma’s slim-down wave, shedding non-core assets and working to strengthen its focus areas. Cancer is high on its priority list, and to that end, it last year agreed to fork over $16 billion in exchange for GlaxoSmithKline’s oncology business–a deal GSK is set to close next week.
 
By Carly Helfand
 

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

November 22, 2020

Belgium is ‘European biotech leader’ for 3rd year in a row

Life sciences

Belgian companies account for just under a quarter (24%) of the total stock market value of all public biotech companies in Europe.

November 22, 2020

J&J, following BMS, pledges $100M to address racism and health inequities

Life sciences

Johnson & Johnson is re-upping its commitment to addressing health inequities as the pandemic lays bare long-standing divisions.

November 22, 2020

Sanofi sponsors Parkinson’s Foundation’s genetic study with $1M for free testing

Life sciences

It’s estimated that 10% to 15% of people with Parkinson’s have a genetic form of the disease and Sanofi Genzyme is backing a new study to help find those people.

Send this to a friend